2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1711 Single-cell multiomics analysis reveals RUNX3 as a key regulator of NK cell fate in acute myeloid leukemia

Jiaxiu Ma, Ruogu Wang, MD2, Qingming Xue, MD3, Haiqing Xiong Sr4
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, China

Introduction

Natural killer (NK) cells serve as critical crucial immune surveillance effectors in the pathogenesis of acute myeloid leukemia (AML), yet the mechanisms that drive their numerical and functional decline remain incompletely understood. Prior work has largely focused on defective effector activity in mature NK cells, leaving unresolved whether cytotoxic NK cells originate at earlier stages of differentiation. Here, we investigated how leukemia-remodeled macrophage niches intersect with cell-intrinsic fate programs to constrain the development of cytotoxic NK cells. 

Methods

We assembled an integrated single-cell atlas comprising 1,354,921 transcriptomes from 213 AML and healthy-donor samples, together with single-cell chromatin-accessibility profiles from 57 samples. We resolved NK cell states through differential-abundance analysis, trajectory inference and pseudotime-resolved gene-module analysis. Branch-associated regulators were identified via regulon reconstruction and in silico perturbation, and we applied ligand–receptor analysis to define microenvironmental signals linked to divergent NK cell fates. Clinical relevance was assessed in Beat AML 1.0 cohort.

Results

NK cells were the most profoundly depleted immune population in AML, with mean abundance decreasing from 2.14% of annotated cells in healthy donors to 0.42% in AML. Among 17,784 NK cells analyzed, cytotoxic NK cells contracted from 52.5% of the NK compartment in healthy donors to 3.4% in AML, whereas low-effector NK cells expanded from 6.2% to 39.4%, indicating selective erosion of cytotoxic identity rather than uniform attrition.

Trajectory reconstruction showed that fate divergence originated in the immature NK cell compartment and became most pronounced at a transitional state, where cells branched toward cytotoxic or low-effector fates. Cytotoxic differentiation was accompanied by coordinated activation of cell-killing programs, whereas these programs failed to consolidate along the low-effector branch. Integrative analysis of branch-resolved transcriptional dynamics, functional modules and regulon activity identified RUNX3 as a candidate regulator of cytotoxic fate acquisition. RUNX3 expression increased along the cytotoxic trajectory and correlated positively with inferred NK cell abundance in Beat AML 1.0 cohort. In silico perturbation of RUNX3 predicted redistribution toward the low-effector state, and lower RUNX3 expression was associated with inferior overall survival.

Cell–cell communication analysis identified macrophages as the predominant immune partners of NK cells. Leukemia-associated macrophage-like cells expressed substantially less IL18 than resident-like macrophages, suggesting loss of a niche-derived differentiation signal. Among macrophage-to-NK interactions, IL18–IL18R1 showed the strongest relative enrichment in cytotoxic versus low-effector NK cells. IL18R1 was more highly expressed in cytotoxic NK cells and embedded within the predicted RUNX3 regulatory network, linking IL-18 responsiveness to cytotoxic fate acquisition. Thus, AML-associated macrophage remodeling reduces IL-18 availability, while NK cells diverted toward the low-effector state fail to establish the RUNX3-linked IL18R1 response program required for cytotoxic differentiation.

Conclusion

We identify a trans-cellular checkpoint that links macrophage-derived IL-18 to a RUNX3-dependent IL18R1 response program in NK cells. Disruption of this checkpoint precedes terminal effector failure and becomes most pronounced at the transitional NK cell state, diverting differentiation away from the cytotoxic fate. Restoring IL-18 signaling or NK cell responsiveness may help recover NK cell competence and reinforce antileukemic immune surveillance.

Jiaxiu Ma: No relevant conflicts of interest to declare.